Fresenius SE EBITDA 2016-2026 | FSNUY
Fresenius SE annual and quarterly EBITDA history from 2016 to 2026. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Fresenius SE EBITDA for the quarter ending June 30, 2026 was $1.047B, a 8.87% increase year-over-year.
- Fresenius SE EBITDA for the twelve months ending June 30, 2026 was $3.990B, a 9.6% increase year-over-year.
- Fresenius SE 2025 annual EBITDA was $3.881B, a 20.1% increase from 2024.
- Fresenius SE 2024 annual EBITDA was $3.231B, a 13.9% increase from 2023.
- Fresenius SE 2023 annual EBITDA was $2.837B, a 57.22% decline from 2022.
|
Fresenius SE Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $3,881 |
| 2024 | $3,231 |
| 2023 | $2,837 |
| 2022 | $6,631 |
| 2021 | $8,075 |
| 2020 | $8,110 |
| 2019 | $7,933 |
| 2018 | $7,890 |
| 2017 | $6,811 |
| 2016 | $6,086 |
| 2015 | $5,541 |
|
Fresenius SE Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $1,047 |
| 2026-03-31 | $1,024 |
| 2025-12-31 | $1,034 |
| 2025-09-30 | $885 |
| 2025-06-30 | $961 |
| 2025-03-31 | $1,000 |
| 2024-12-31 | $833 |
| 2024-09-30 | $846 |
| 2024-06-30 | $629 |
| 2024-03-31 | $923 |
| 2023-12-31 | $82 |
| 2023-09-30 | $-217 |
| 2023-06-30 | $1,372 |
| 2023-03-31 | $1,600 |
| 2022-12-31 | $1,664 |
| 2022-09-30 | $1,592 |
| 2022-06-30 | $1,586 |
| 2022-03-31 | $1,790 |
| 2021-12-31 | $2,177 |
| 2021-09-30 | $1,933 |
| 2021-06-30 | $2,002 |
| 2021-03-31 | $1,963 |
| 2020-12-31 | $2,128 |
| 2020-09-30 | $2,107 |
| 2020-06-30 | $1,939 |
| 2020-03-31 | $1,936 |
| 2019-12-31 | $2,171 |
| 2019-09-30 | $1,940 |
| 2019-06-30 | $1,907 |
| 2019-03-31 | $1,915 |
| 2018-12-31 | $1,852 |
| 2018-09-30 | $1,597 |
| 2018-06-30 | $2,739 |
| 2018-03-31 | $1,702 |
| 2017-12-31 | $1,680 |
| 2017-09-30 | $1,776 |
| 2017-06-30 | $1,692 |
| 2017-03-31 | $1,662 |
| 2016-12-31 | $1,695 |
| 2016-09-30 | $1,506 |
| 2016-06-30 | $1,520 |
| 2016-03-31 | $1,365 |
| 2015-12-31 | $7,951 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $29.581B | $25.873B |
| Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quest Diagnostics (DGX) | United States | $27.271B | 23.22 |
| DaVita (DVA) | United States | $12.179B | 14.91 |
| Encompass Health (EHC) | United States | $12.036B | 20.89 |
| Elanco Animal Health (ELAN) | United States | $11.491B | 21.70 |
| Chemed (CHE) | United States | $6.620B | 23.60 |
| RadNet (RDNT) | United States | $6.069B | 175.27 |
| LifeStance Health (LFST) | United States | $4.991B | 100.46 |
| Option Care Health (OPCH) | United States | $3.523B | 14.89 |
| Aveanna Healthcare Holdings (AVAH) | United States | $3.123B | 21.68 |
| Addus HomeCare (ADUS) | United States | $2.164B | 19.57 |
| Astrana Health (ASTH) | United States | $2.138B | 22.69 |
| Pennant (PNTG) | United States | $1.396B | 36.34 |
| U.S Physical Therapy (USPH) | United States | $1.220B | 32.19 |
| Daxor (DXR) | United States | $0.065B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.024B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |